205 related articles for article (PubMed ID: 28289895)
1. Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries.
Geissler J; Sharf G; Bombaci F; Daban M; De Jong J; Gavin T; Pelouchova J; Dziwinski E; Hasford J; Hoffmann VS
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1167-1176. PubMed ID: 28289895
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib.
Unnikrishnan R; Veeraiah S; Mani S; Rajendranath R; Rajaraman S; Vidhubala Elangovan GS; Radhakrishnan V; Ganesan TS; Sagar TG; Ganesan P
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):366-371.e3. PubMed ID: 27052853
[TBL] [Abstract][Full Text] [Related]
3. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan.
Tsai YF; Huang WC; Cho SF; Hsiao HH; Liu YC; Lin SF; Liu TC; Chang CS
Medicine (Baltimore); 2018 Jun; 97(26):e11322. PubMed ID: 29953021
[TBL] [Abstract][Full Text] [Related]
4. Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study.
Jönsson S; Olsson B; Söderberg J; Wadenvik H
Ann Hematol; 2012 May; 91(5):679-685. PubMed ID: 22048790
[TBL] [Abstract][Full Text] [Related]
5. Cultural factors related to adherence to imatinib in CML: a Mexican perspective.
Cantú-Rodríguez OG; Sánchez-Cárdenas M; Gutiérrez-Aguirre CH; Jaime-Pérez JC; Mancias-Guerra C; González-Llano O; Gómez-Almaguer D
Hematology; 2015 Mar; 20(2):72-6. PubMed ID: 25034734
[TBL] [Abstract][Full Text] [Related]
6. Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia.
Hosoya K; Mochinaga S; Emoto A; Yokoo H; Tokushima H; Egoshi M; Sueoka-Aragane N; Kimura S
Int J Clin Oncol; 2015 Dec; 20(6):1203-10. PubMed ID: 26002407
[TBL] [Abstract][Full Text] [Related]
7. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.
Breccia M; Efficace F; Sica S; Abruzzese E; Cedrone M; Turri D; Gobbi M; Carella AM; Gozzini A; Usala E; Cavazzini F; Danise P; Tiribelli M; Binotto G; Pregno P; Bocchia M; Gaidano G; Crugnola M; Bonifacio M; Avanzini P; Celesti F; Guella A; Martino B; Annunziata M; Luciano L; Stagno F; Vallisa D; Pungolino E; Iurlo A; Rambaldi A; Nardiello I; Orlandi E; Gambacorti-Passerini C; Alimena G
Leuk Res; 2015 Oct; 39(10):1055-9. PubMed ID: 26282944
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial.
Tan BK; Chua SS; Chen LC; Chang KM; Balashanker S; Bee PC
Support Care Cancer; 2020 Jul; 28(7):3237-3247. PubMed ID: 31734798
[TBL] [Abstract][Full Text] [Related]
9. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.
Gater A; Heron L; Abetz-Webb L; Coombs J; Simmons J; Guilhot F; Rea D
Leuk Res; 2012 Jul; 36(7):817-25. PubMed ID: 22364811
[TBL] [Abstract][Full Text] [Related]
10. Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors.
Hefner J; Csef EJ; Kunzmann V
Oncol Nurs Forum; 2017 Nov; 44(6):E232-E240. PubMed ID: 29052661
[TBL] [Abstract][Full Text] [Related]
11. Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study.
Kekäle M; Söderlund T; Koskenvesa P; Talvensaari K; Airaksinen M
J Adv Nurs; 2016 Sep; 72(9):2196-206. PubMed ID: 27113362
[TBL] [Abstract][Full Text] [Related]
12. Adherence trajectories in oral therapy for chronic myeloid leukemia: Overview of a research protocol.
Yeager KA; Waldrop-Valverde D; Paul S; Bruner DW; Klisovic R; Burns E; Mason TA; Patel N; Jennings BM
Res Nurs Health; 2020 Sep; 43(5):443-452. PubMed ID: 32866350
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian's with chronic myeloid leukemia.
Mulu Fentie A; Tadesse F; Engidawork E; Gebremedhin A
PLoS One; 2019; 14(3):e0213557. PubMed ID: 30845227
[TBL] [Abstract][Full Text] [Related]
14. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.
Eliasson L; Clifford S; Barber N; Marin D
Leuk Res; 2011 May; 35(5):626-30. PubMed ID: 21095002
[TBL] [Abstract][Full Text] [Related]
15. Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia.
Goldberg SL; Akard LP; Dugan MJ; Faderl S; Pecora AL
J Oncol Pract; 2015 May; 11(3):e398-404. PubMed ID: 25758446
[TBL] [Abstract][Full Text] [Related]
16. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
17. Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study.
Leader A; Gafter-Gvili A; Benyamini N; Dreyer J; Calvarysky B; Amitai A; Yarchovsky-Dolberg O; Sharf G; Tousset E; Caspi O; Ellis M; Levi I; Raanani P; De Geest S
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):e351-e362. PubMed ID: 30122203
[TBL] [Abstract][Full Text] [Related]
18. Study on adherence to treatment with imatinib in chronic myeloid leukaemia and its association with therapeutic response.
García-Queiruga M; Martínez-López LM; Martín-Herranz MI; Seoane-Pillado T; Fernández-Gabriel E; Calleja-Chuclá T
Farm Hosp; 2016 May; 40(3):141-9. PubMed ID: 27145384
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic observance in haematology: the particular case of chronic myeloid leukemia].
Roufosse R; Beguin Y
Rev Med Liege; 2010; 65(5-6):409-12. PubMed ID: 20684429
[TBL] [Abstract][Full Text] [Related]
20. Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study.
Wu S; Chee D; Ugalde A; Butow P; Seymour J; Schofield P
Palliat Support Care; 2015 Apr; 13(2):255-63. PubMed ID: 24524212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
